Cerulean and Dar to Host Conference Call on Proposed Transaction on March 23
[End Subhead]
[Start Distributor]
Business Wire 20-Mar-2017 9:38 PM
[End Distributor]
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Dar Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Dar Bioscience will become the majority owners of Cerulean.
The conference call will take place at 9:00 a.m. ET on Thursday, March 23, 2017. This call can be accessed by dialing 443-637-1284 or 844-831-3031 prior to the start of the call and referencing conference ID 91378612.
The conference call also will be webcast live over theInternetand can be accessed on the "Investors" section of the Cerulean website,www.ceruleanrx.com. The webcast will be archived on the Company's website until March 31, 2017.
About Dar Bioscience
Dar Bioscience is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for womens reproductive health. Dar is committed to advancing novel clinical-stage candidates in womens reproductive health to expand options and improve outcomes. Product developmentin womens reproductive health is fragmented creating a potential opportunity for Dar.Our goal is to fill the gap by taking products from innovation through development the Dar team is well-suited to ensure these products advance and are one day commercially available. The founders bring experience in global womens healthcare as well as success in prior ventures in funding, achieving regulatory approvals, partnering, and launching a number of products, including devices, therapeutics and diagnostics. For more information on the company, please visit www.darebioscience.com.
About Cerulean Pharma
Cerulean is a company focused on applying the Dynamic Tumor Targeting Platform to create nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations.
Additional Information about the Proposed Transaction and Where to Find It
In connection with the proposed Dar transaction, Cerulean intends to file relevant materials with the Securities and Exchange Commission (the SEC), including a definitive proxy statement on Schedule 14A (the Proxy Statement). The Proxy Statement will be sent or given to the stockholders of Cerulean and will contain important information about the proposed transaction and related matters. BEFORE MAKING ANY VOTING DECISION, CERULEANS STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THOSE OTHER MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. The Proxy Statement and other relevant materials (when they become available), and any other documents filed by Cerulean with the SEC, may be obtained free of charge at the SECs website at www.sec.gov. In addition, security holders will be able to obtain free copies of the proxy statement by directing a written request to: Cerulean Pharma Inc., 35 Gatehouse Drive, Waltham, MA, Attention: Corporate Secretary.
Participants in the Solicitation
Cerulean, Dar, and each of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Cerulean in connection with the proposed transaction described herein. Information regarding the interests of these directors and executive officers in the proposed transaction described herein will be included in the Proxy Statement described above. Additional information regarding the directors and executive officers of Cerulean is included in proxy statement for its 2016 Annual Meeting, which was filed with the SEC on April 28, 2016, and is supplemented by other public filings made, and to be made, with the SEC by Cerulean.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170320006337/en/
CeruleanChris Guiffre, 781-209-6450orDarSabrina Martucci Johnson, 858-769-9145
Source: Cerulean Pharma Inc.

Wait, Before You Leave...